Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

C.J. Ryan; M. Rosenthal; S. Ng; J. Alumkal; J. Picus; G. Gravis; K. Fizazi; F. Forget; J.P. Machiels; S. Srinivas; M. Zhu; R. Tang; K.S. Oliner; Y.Z. Jiang; E. Loh; S. Dubey; W.R. Gerritsen

doi:10.1158/1078-0432.CCR-12-2605

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

C.J. Ryan, M. Rosenthal, S. Ng, J. Alumkal, J. Picus, G. Gravis, K. Fizazi, F. Forget, J.P. Machiels, S. Srinivas, M. Zhu, R. Tang, K.S. Oliner, Y.Z. Jiang, E. Loh, S. Dubey, W.R. Gerritsen

Medical oncology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	215-224
Journal	Clinical Cancer Research
Volume	19
Issue number	1
DOIs	https://doi.org/10.1158/1078-0432.CCR-12-2605
Publication status	Published - 2013

Cite this

Ryan, C. J., Rosenthal, M., Ng, S., Alumkal, J., Picus, J., Gravis, G., ... Gerritsen, W. R. (2013). Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. Clinical Cancer Research, 19(1), 215-224. https://doi.org/10.1158/1078-0432.CCR-12-2605

Ryan, C.J. ; Rosenthal, M. ; Ng, S. ; Alumkal, J. ; Picus, J. ; Gravis, G. ; Fizazi, K. ; Forget, F. ; Machiels, J.P. ; Srinivas, S. ; Zhu, M. ; Tang, R. ; Oliner, K.S. ; Jiang, Y.Z. ; Loh, E. ; Dubey, S. ; Gerritsen, W.R. / Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 1. pp. 215-224.

@article{6234b7d14d554b60853ce436d9f681cf,

title = "Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone",

author = "C.J. Ryan and M. Rosenthal and S. Ng and J. Alumkal and J. Picus and G. Gravis and K. Fizazi and F. Forget and J.P. Machiels and S. Srinivas and M. Zhu and R. Tang and K.S. Oliner and Y.Z. Jiang and E. Loh and S. Dubey and W.R. Gerritsen",

year = "2013",

doi = "10.1158/1078-0432.CCR-12-2605",

language = "Undefined/Unknown",

volume = "19",

pages = "215--224",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

Ryan, CJ, Rosenthal, M, Ng, S, Alumkal, J, Picus, J, Gravis, G, Fizazi, K, Forget, F, Machiels, JP, Srinivas, S, Zhu, M, Tang, R, Oliner, KS, Jiang, YZ, Loh, E, Dubey, S & Gerritsen, WR 2013, 'Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone', Clinical Cancer Research, vol. 19, no. 1, pp. 215-224. https://doi.org/10.1158/1078-0432.CCR-12-2605

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. / Ryan, C.J.; Rosenthal, M.; Ng, S.; Alumkal, J.; Picus, J.; Gravis, G.; Fizazi, K.; Forget, F.; Machiels, J.P.; Srinivas, S.; Zhu, M.; Tang, R.; Oliner, K.S.; Jiang, Y.Z.; Loh, E.; Dubey, S.; Gerritsen, W.R.

In: Clinical Cancer Research, Vol. 19, No. 1, 2013, p. 215-224.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

AU - Ryan, C.J.

AU - Rosenthal, M.

AU - Ng, S.

AU - Alumkal, J.

AU - Picus, J.

AU - Gravis, G.

AU - Fizazi, K.

AU - Forget, F.

AU - Machiels, J.P.

AU - Srinivas, S.

AU - Zhu, M.

AU - Tang, R.

AU - Oliner, K.S.

AU - Jiang, Y.Z.

AU - Loh, E.

AU - Dubey, S.

AU - Gerritsen, W.R.

PY - 2013

Y1 - 2013

U2 - 10.1158/1078-0432.CCR-12-2605

DO - 10.1158/1078-0432.CCR-12-2605

M3 - Article

C2 - 23136195

VL - 19

SP - 215

EP - 224

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -

Access to Document

10.1158/1078-0432.CCR-12-2605